462 related articles for article (PubMed ID: 35832441)
1. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study.
Yang J; Zeng R; Zhou J; Luo L; Lyu M; Liu F; Sun X; Zhou L; Wang X; Bao Z; Chen W; Dumoulin DW; Gao B; Xiang Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1038-1050. PubMed ID: 35832441
[TBL] [Abstract][Full Text] [Related]
2. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
Front Immunol; 2021; 12():730320. PubMed ID: 34646270
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
Torasawa M; Yoshida T; Takeyasu Y; Shimoda Y; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
Cancer Med; 2023 Jun; 12(11):12388-12401. PubMed ID: 37062059
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
7. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody
Fujisaki T; Watanabe S; Ota T; Kushiro K; Sato Y; Takahashi M; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Hokari S; Kondo R; Miyabayashi T; Abe T; Miura S; Tanaka H; Okajima M; Terada M; Matsumoto N; Ishida T; Iwashima A; Sato K; Yoshizawa H; Aoki N; Hayashi M; Ohshima Y; Koya T; Kikuchi T
Front Oncol; 2021; 11():704475. PubMed ID: 34631533
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.
Simonaggio A; Michot JM; Voisin AL; Le Pavec J; Collins M; Lallart A; Cengizalp G; Vozy A; Laparra A; Varga A; Hollebecque A; Champiat S; Marabelle A; Massard C; Lambotte O
JAMA Oncol; 2019 Sep; 5(9):1310-1317. PubMed ID: 31169866
[TBL] [Abstract][Full Text] [Related]
10. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
Dolladille C; Ederhy S; Sassier M; Cautela J; Thuny F; Cohen AA; Fedrizzi S; Chrétien B; Da-Silva A; Plane AF; Legallois D; Milliez PU; Lelong-Boulouard V; Alexandre J
JAMA Oncol; 2020 Jun; 6(6):865-871. PubMed ID: 32297899
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events.
Guo M; VanderWalde AM; Yu X; Vidal GA; Tian GG
Clin Lung Cancer; 2022 Dec; 23(8):686-693. PubMed ID: 36050243
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis.
Xu S; Shukuya T; Tamura J; Shimamura S; Kurokawa K; Miura K; Miyawaki T; Hayakawa D; Asao T; Yamamoto K; Takahashi K
JTO Clin Res Rep; 2022 Apr; 3(4):100309. PubMed ID: 35434666
[TBL] [Abstract][Full Text] [Related]
14. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study.
Lin X; Deng H; Chu T; Chen L; Yang Y; Qiu G; Xie X; Qin Y; Liu M; Xie Z; Ouyang M; Li S; Song Y; Petrella F; Jakopovic M; Tsoukalas N; Solli P; Goto T; Saito Y; Zhou C
Transl Lung Cancer Res; 2022 Nov; 11(11):2289-2305. PubMed ID: 36519018
[TBL] [Abstract][Full Text] [Related]
16. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
17. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
Nizam A; Rader RK; Tzeng A; Wei W; Sheng IY; Martin A; Wee CE; Gilligan TD; Gupta S; Ornstein MC
Clin Genitourin Cancer; 2024 Apr; 22(2):368-379. PubMed ID: 38245437
[TBL] [Abstract][Full Text] [Related]
19. Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.
Sugisaka J; Toi Y; Taguri M; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
JMA J; 2020 Jan; 3(1):58-66. PubMed ID: 33324776
[TBL] [Abstract][Full Text] [Related]
20. Use of the prognostic nutrition index as a predictive biomarker in small-cell lung cancer patients undergoing immune checkpoint inhibitor treatment in the Chinese alpine region.
Wu Y; Yang J; Qiao X; Li Y; Zhao R; Lin T; Li X; Wang M
Front Oncol; 2023; 13():1041140. PubMed ID: 37007079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
